Guideline No. 390-Classification and Management of Endometrial Hyperplasia



      The aim of this guideline is to aid primary care physicians and gynaecologists in the initial evaluation of women with suspected endometrial hyperplasia, to recommend the use of the 2014 World Health Organization classification for endometrial hyperplasia by all health care providers, and to guide the optimal treatment of women diagnosed with endometrial hyperplasia.

      Intended Users

      Physicians, including gynaecologists, obstetricians, family physicians, general surgeons, emergency medicine specialists; nurses, including registered nurses and nurse practitioners; medical trainees, including medical students, residents, and fellows; and all other health care providers.

      Target Population

      Adult women (18 years and older) presenting with suspected or confirmed endometrial hyperplasia.


      The discussion relates to the medical therapy as well as surgical treatment options for women with and without atypical endometrial hyperplasia.


      For this guideline, relevant studies were searched in PubMed, Cochrane Wiley, and the Cochrane Systematic Reviews using the following terms, either alone or in combination, with the search limited to English language materials, human subjects, and published since 2000: (endometrial hyperplasia, endometrial intraepithelial neoplasia, endometrial sampling, endometrial curettage, diagnosis) AND (treatment, progestin therapy, surgery, LNG-IUS, aromatase inhibitors, metformin ), AND (obesity). The search was performed in April 2018. Relevant evidence was selected for inclusion in the following order: meta-analyses, systematic reviews, guidelines, randomized controlled trials, prospective cohort studies, observational studies, non-systematic reviews, case series, and reports. Additional significant articles were identified through cross-referencing the identified reviews. The total number of studies identified was 2152, and 82 studies were included in this review.

      Validation Methods

      The content and recommendations were drafted and agreed upon by the authors. The Executive and Board of the Society of Gynecologic Oncology of Canada reviewed the content and submitted comments for consideration, and the Board of the Society of Obstetricians and Gynaecologists of Canada approved the final draft for publication. The quality of evidence was rated using the criteria described in the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology framework. The interpretation of strong and weak recommendations was also included. The Summary of Findings is available upon request.

      Benefits, Harms, and/or Costs

      It is expected that this guideline will benefit women with endometrial hyperplasia. This should guide patient informed consent before both medical and surgical management of this condition.

      Guideline Update

      Evidence will be reviewed 5 years after publication to decide whether all or part of the guideline should be updated. However, if important new evidence is published prior to the 5-year cycle, the review process may be accelerated for a more rapid update of some recommendations.

      Summary Statements

      • 1
        In addition to epidemiologic risk factors related to estrogen exposure, intermenstrual bleeding and postmenopausal bleeding are associated with increased risk of endometrial hyperplasia. Endometrial sampling should be carried out as per published algorithms with particular attention to women 40 years or older or with a body mass index of 30 kg/m2 or greater (moderate).
      • 2
        Since the majority of cases of endometrial hyperplasia without atypia are successfully managed medically, hysterectomy is not considered first-line treatment and surgery is reserved for specific circumstances (moderate).
      • 3
        A minimally invasive approach to hysterectomy is preferred for endometrial hyperplasia as it decreases perioperative morbidity and mortality (high).
      • 4
        If hysterectomy is indicated for endometrial hyperplasia without atypia then postmenopausal women should also be offered bilateral salpingo-oophorectomy. This decision is individualized for premenopausal women due to increased mortality and morbidity associated with removal of the ovaries in young women with benign disease (moderate).
      • 5
        Hysterectomy and bilateral salpingo-oophorectomy are the recommended treatment for atypical endometrial hyperplasia due to the underlying risk of malignancy or progression to endometrial cancer. Retention of the ovaries in premenopausal women may be considered (low).
      • 6
        There is no evidence to support routine intraoperative frozen section analysis in cases of endometrial hyperplasia (low).
      • 7
        There is no evidence to support routine lymphadenectomy for atypical endometrial hyperplasia (moderate).
      • 8
        There is insufficient evidence to support endometrial ablation as first-line surgical treatment for endometrial hyperplasia without atypia (low).
      • 9
        Endometrial hyperplasia found in endometrial polyps should be treated according to its histologic classification (low).


      • 1
        Health care providers should use the 2014 World Health Organization histopathologic classification of endometrial hyperplasia (strong, low). If endometrial cancer is suspected, endometrial tissue sampling using a Pipelle device in an outpatient setting is the most appropriate first step for diagnosis (strong, high).
      • 2
        Those with recurrent symptoms of abnormal uterine bleeding after initial observation or medical treatment should be reassessed with an endometrial biopsy (strong, high).
      • 3
        Patients with endometrial hyperplasia should be assessed for reversible risk factors and receive education and support from their clinicians in order to treat and reverse those conditions (strong, high).
      • 4
        Patients with endometrial hyperplasia without atypia can be observed. They can be offered hormonal treatment if hyperplasia does not resolve with observation or experience abnormal uterine bleeding (weak, low).
      • 5
        The levonorgestrel intrauterine system should be used as the first-line treatment for endometrial hyperplasia without atypia due to its effectiveness and favourable side effect profile (strong, high) and due to the fact that it can be kept in place for 5 years in patients showing treatment response (strong, moderate).
      • 6
        Low-dose oral and injectable progestins remain an acceptable treatment option for women with endometrial hyperplasia with and without atypia desiring an alternative treatment modality (strong, high). For patients on oral progestins, we suggest starting on a low dose for a minimum of 6 months. We suggest that assessment of the endometrium be done mid-therapy as well as 3 weeks after completion of treatment to ensure proper interpretation (strong, very low).
      • 7
        Surgical treatment of endometrial hyperplasia without atypia should be reserved for patients who do not want to preserve their fertility and experience progression to atypical hyperplasia or carcinoma during follow-up, whose hyperplasia fails to regress after 12 months of medical treatment or relapses after completing treatment with progestins, who continue to experience abnormal uterine bleeding despite treatment, or who decline endometrial surveillance or medical treatment (strong, high).
      • 8
        If surgery is indicated for endometrial hyperplasia without atypia, the procedure should include total hysterectomy with opportunistic salpingectomy, with or without bilateral oophorectomy depending on menopausal status (strong, moderate).
      • 9
        Total hysterectomy with bilateral salpingo-oophorectomy is recommended for treatment of atypical hyperplasia in premenopausal and postmenopausal women (strong, moderate). In premenopausal women, ovarian preservation should be discussed (strong, moderate).
      • 10
        We recommend that subtotal (supracervical) hysterectomy and morcellation be avoided in all cases of endometrial hyperplasia (strong, low).

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Obstetrics and Gynaecology Canada
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Reed SD
        • Newton KM
        • Clinton WL
        • et al.
        Incidence of endometrial hyperplasia.
        Am J Obstet Gynecol. 2009; 200 (678.e1–6)
        • Abu Hashim H
        • Ghayaty E
        • El Rakhawy M
        Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: a systematic review and meta-analysis of randomized trials.
        Am J Obstet Gynecol. 2015; 213: 469-478
        • Emons G
        • Beckmann MW
        • Schmidt D
        • et al.
        New who classification of endometrial hyperplasias.
        Geburtshilfe Frauenheilkd. 2015; 75: 135-136
        • Zaino R
        • Carinelli SG
        • Ellenson LH
        • et al.
        WHO Classification of Tumours of Female Reproductive Organs.
        4th edition ed. WHO Press, Lyon, France2014: 125-126
        • Moore E
        • Shafi M
        Endometrial hyperplasia.
        Obstet Gynaecol Reprod Med. 2013; 23: 88-93
        • Kandoth C
        • Schultz N
        • et al.
        • The Cancer Genome Atlas Research Network
        Integrated genomic characterization of endometrial carcinoma.
        Nature. 2013; 497: 67-73
        • Antonsen SL
        • Ulrich L
        • Høgdall C
        Patients with atypical hyperplasia of the endometrium should be treated in oncological centers.
        Gynecol Oncol. 2012; 125: 124-128
        • Chandra V
        • Kim JJ
        • Benbrook DM
        • et al.
        Therapeutic options for management of endometrial hyperplasia.
        J Gynecol Oncol. 2016; 27: e8
        • Fraser IS
        • Critchley HO
        • Broder M
        • et al.
        The FIGO recommendations on terminologies and definitions for normal and abnormal uterine bleeding.
        Semin Reprod Med. 2011; 29: 383-390
        • Pennant ME
        • Mehta R
        • Moody P
        • et al.
        Premenopausal abnormal uterine bleeding and risk of endometrial cancer.
        BJOG. 2017; 124: 404-411
        • Renaud MC
        • Le T
        • SOGC-GOC-SCC Policy and Practice Guidelines Committee
        Epidemiology and investigations for suspected endometrial cancer.
        J Obstet Gynaecol Can. 2013; 35: 380-381
        • Singh S
        • Best C
        • Dunn S
        • et al.
        Abnormal uterine bleeding in pre-menopausal women (replaces No. 106, Aug 2001).
        J Obstet Gynaecol Can. 2013; 35: S1-28
        • Tram S
        • Musonda P
        • Ewies AA
        Premenopausal bleeding: when should the endometrium be investigated? A retrospective non-comparative study of 3006 women.
        Eur J Obstet Gynecol Reprod Biol. 2010; 148: 86-89
        • Wise MR
        • Gill P
        • Lensen S
        • et al.
        Body mass index trumps age in decision for endometrial biopsy: cohort study of symptomatic premenopausal women.
        Am J Obstet Gynecol. 2016; 215 (598.e1–8)
        • Dijkhuizen FP
        • Mol BW
        • Brolmann HA
        • et al.
        The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia.
        Cancer. 2000; 89: 1765-1772
        • Sherman ME
        • Ronnett B
        • Ioofe O
        • et al.
        Reproducibility of biopsy diagnoses of endometrial hyperplasia: evidence supporting a simplified classification.
        Int J Gynecol Pathol. 2008; 27: 318-325
        • Wheeler DT
        • Bristow RE
        • Kurman RJ
        Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
        Am J Surg Pathol. 2007; 31: 988-998
        • Beavis AL
        • Cheema S
        • Holschneider CH
        • et al.
        Almost half of women with endometrial cancer or hyperplasia do not know that obesity affects their cancer risk.
        Gynecol Oncol Rep. 2015; 13: 71-75
      1. Sanguakeo A, Upala S.Bariatric surgery and risk of postoperative endometrial cancer: a systematic review and meta-analysis. Surg Obes Relat Dis 11:949–55.

        • Committee on Gynecologic Practice Society of Gynecologic Oncology
        The American College of Obstetricians and Gynecologists committee opinion no. 631. Endometrial intraepithelial neoplasia.
        Obstet Gynecol. 2015; 125: 1272-1278
        • Kurman RJ
        • Kaminski PF
        • Norris HJ
        The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients.
        Cancer. 1985; 56: 403-412
        • Terakawa N
        • Kigawa J
        • Taketani Y
        • et al.
        The behavior of endometrial hyperplasia: a prospective study.
        Endometrial Hyperplasia Study Group. J Obstet Gynaecol Res. 1997; 23: 223-230
        • Lacey Jr, JV
        • Sherman ME
        • Rush BB
        • et al.
        Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia.
        J Clin Oncol. 2010; 28: 788-792
        • Ismail MT
        • Fahmy DM
        • Elshmaa NS
        Efficacy of levonorgestrel-releasing intrauterine system versus oral progestins in treatment of simple endometrial hyperplasia without atypia.
        Reprod Sci. 2013; 20: 45-50
        • Dolapcioglu K
        • Boz A
        • Baloglu A
        The efficacy of intrauterine versus oral progestin for the treatment of endometrial hyperplasia. A prospective randomized comparative study.
        Clin Exp Obstet Gynecol. 2013; 40: 122-126
        • Abu Hashim H
        • Zayed A
        • Ghayaty E
        • et al.
        LNG-IUS treatment of non-atypical endometrial hyperplasia in perimenopausal women: a randomized controlled trial.
        J Gynecol Oncol. 2013; 24: 128-134
        • Karimi-Zarchi M
        • Dehghani-Firoozabadi R
        • Tabatabaie A
        • et al.
        A comparison of the effect of levonorgestrel IUD with oral medroxyprogesterone acetate on abnormal uterine bleeding with simple endometrial hyperplasia and fertility preservation.
        Clin Exp Obstet Gynecol. 2013; 40: 421-424
        • Behnamfar F
        • Ghahiri A
        • Tavakoli M
        Levonorgestrel-releasing intrauterine system (Mirena) in compare to medroxyprogesterone acetate as a therapy for endometrial hyperplasia.
        J Res Med Sci. 2014; 19: 686-690
        • Ørbo A
        • Vereide AB
        • Arnes M
        • et al.
        Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial.
        BJOG. 2014; 121: 477-486
        • El Behery MM
        • Saleh HS
        • Ibrahiem MA
        • et al.
        Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia.
        Reprod Sci. 2015; 22: 329-334
      2. Abdelaziz AM, Abosrie M. Levonorgestrel-releasing intrauterine system is an efficient therapeutic modality for simple endometrial hyperplasia. J Am Sci 2013:417–24.

        • Nooh AM
        • Abdeldayem HM
        • Girbash EF
        • et al.
        Depo-Provera versus norethisterone acetate in management of endometrial hyperplasia without atypia.
        Reprod Sci. 2016; 23: 448-454
        • Moradan S
        • Nikkhah N
        • Mirmohammadkhanai M
        Comparing the administration of letrozole and megestrol acetate in the treatment of women with simple endometrial hyperplasia without atypia: a randomized clinical trial.
        Adv Ther. 2017; 34: 1211-1220
        • Gunderson CC
        • Fader AN
        • Carson KA
        • et al.
        Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review.
        Gynecol Oncol. 2012; 125: 477-482
        • Armstrong AJ
        • Hurd WW
        • Elguero S
        • et al.
        Diagnosis and management of endometrial hyperplasia.
        J Minim Invasive Gynecol. 2012; 19: 562-571
        • Gallos ID
        • Shehmar M
        • Thangaratinam S
        • et al.
        Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: A systematic review and metaanalysis.
        Am J Obstet Gynecol. 2010; 203 (547.e1–10)
        • Gallos ID
        • Krishan P
        • Shehmar M
        • et al.
        LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study.
        Hum Reprod. 2013; 28: 2966-2971
        • Gallos ID
        • Ganesan R
        • Gupta JK
        Prediction of regression and relapse of endometrial hyperplasia with conservative therapy.
        Obstet Gynecol. 2013; 121: 1165-1171
        • Gallos ID
        • Alazzam M
        • Clark TJ
        • et al.
        Management of endometrial hyperplasia. Green-top guideline No 67.
        Royal College of Obstetricians and Gynaecologists, London2016 (Available at:)
        • Gallos ID
        • Yap J
        • Rajkhowa M
        • et al.
        Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: A systematic review and metaanalysis.
        Am J Obstet Gynecol. 2012; 207 (e1–12): 266
        • Trimble CL
        • Method M
        • Leitao M
        • et al.
        Management of endometrial precancers.
        Obstet Gynecol. 2012; 120: 1160-1175
        • Simpson AN
        • Feigenberg T
        • Clarke BA
        • et al.
        Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin.
        Gynecol Oncol. 2014; 133: 229-233
        • Chen M
        • Jin Y
        • Li Y
        • et al.
        Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer.
        Int J Gynaecol Obstet. 2016; 132: 34-38
        • Pronin SM
        • Novikova OV
        • Andreeva JY
        • et al.
        Fertility-sparing treatment of early endometrial cancer and complex atypical hyperplasia in young women of childbearing potential.
        Int J Gynecol Cancer. 2015; 25: 1010-1014
        • Ohyagi-Hara C
        • Sawada K
        • Aki I
        • et al.
        Efficacies and pregnancy outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature.
        Arch Gynecol Obstet. 2015; 291: 151-157
        • Shan W
        • Wang C
        • Zhang Z
        • et al.
        Conservative therapy with metformin plus megestrol acetate for endometrial atypical hyperplasia.
        J Gynecol Oncol. 2014; 25: 214-220
        • Mitsuhashi A
        • Sato Y
        • Kiyokawa T
        • et al.
        Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.
        Ann Oncol. 2016; 27: 262-266
        • Ørbo A
        • Arnes M
        • Vereide AB
        • et al.
        Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens.
        BJOG. 2016; 123: 1512-1519
        • Park JY
        • Lee SH
        • Seong SJ
        • et al.
        Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin.
        Gynecol Oncol. 2013; 129: 7-11
        • Kudesia R
        • Singer T
        • Caputo TA
        • et al.
        Reproductive and oncologic outcomes after progestin therapy for endometrial complex atypical hyperplasia or carcinoma.
        Am J Obstet Gynecol. 2014; 210 (255.e14)
        • Yang YF
        • Liao YY
        • Liu XL
        Prognostic factors of regression and relapse of complex atypical hyperplasia and well-differentiated endometrioid carcinoma with conservative treatment.
        Gynecol Oncol. 2015; 139: 419-423
        • Li M
        • Song JL
        • Zhao Y
        • et al.
        Fertility outcomes in infertile women with complex hyperplasia or complex atypical hyperplasia who received progestin therapy and in vitro fertilization.
        J Zhejiang Univ Sci B. 2017; 18: 1022-1025
        • Gonthier C
        • Piel B
        • Touboul C
        • et al.
        Cancer incidence in patients with atypical endometrial hyperplasia managed by primary hysterectomy or fertility-sparing treatment.
        Anticancer Res. 2015; 35: 6799-6804
        • Ichinose M
        • Fujimoto A
        • Osuga Y
        • et al.
        The influence of infertility treatment on the prognosis of endometrial cancer and atypical complex endometrial hyperplasia.
        Int J Gynecol Cancer. 2013; 23: 288-293
        • Gressel GM
        • Parkash V
        • Pal L
        Management options and fertility-preserving therapy for premenopausal endometrial hyperplasia and early-stage endometrial cancer.
        Int J Gynaecol Obstet. 2015; 131: 234-239
        • Gallos ID
        • Krishan P
        • Shehmar M
        • et al.
        Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up.
        Hum Reprod. 2013; 28: 1231-1236
        • Parker WH
        • Feskanich D
        • Broder MS
        • et al.
        Long-term mortality associated with oophorectomy compared with ovarian conservation in the Nurses’ Health Study.
        Obstet Gynecol. 2013; 121: 709-716
        • Salvador S
        • Scott S
        • Francis JA
        • et al.
        No. 344-Opportunistic salpingectomy and other methods of risk reduction for ovarian/fallopian tube/peritoneal cancer in the general population.
        J Obstet Gynaecol Can. 2017; 39: 480-493
        • Trimble CL
        • Kauderer J
        • Zaino R
        • et al.
        Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study.
        Cancer. 2006; 106: 812-819
        • Rakha E
        • Wong SC
        • Soomro I
        • et al.
        Clinical outcome of atypical endometrial hyperplasia diagnosed on an endometrial biopsy: institutional experience and review of literature.
        Am J Surg Pathol. 2012; 36: 1683-1690
        • Whyte JS
        • Gurney EP
        • Curtin JP
        • et al.
        Lymph node dissection in the surgical management of atypical endometrial hyperplasia.
        Am J Obstet Gynecol. 2010; 202 (176.e1–4)
        • Taşkın S
        • Kan Ö
        • Dai Ö
        • et al.
        Lymph node dissection in atypical endometrial hyperplasia.
        J Turk Ger Gynecol Assoc. 2017; 18: 127-132
        • Giede KC
        • Yen TW
        • Chibbar R
        • et al.
        Significance of concurrent endometrial cancer in women with a preoperative diagnosis of atypical endometrial hyperplasia.
        J Obstet Gynaecol Can. 2008; 30: 896-901
        • Vilos GA
        • Oraif A
        • Vilos AG
        • et al.
        Long-term clinical outcomes following resectoscopic endometrial ablation of non-atypical endometrial hyperplasia in women with abnormal uterine bleeding.
        J Minim Invasive Gynecol. 2015; 22: 66-77
        • Galaal K
        • Bryant A
        • Fisher AD
        • et al.
        Laparoscopy versus laparotomy for the management of early stage endometrial cancer.
        Cochrane Database Syst Rev. 2012; 9CD006655
        • Boyraz G
        • Başaran D
        • Salman MC
        • et al.
        Does preoperative diagnosis of endometrial hyperplasia necessitate intraoperative frozen section consultation?.
        Balkan Med J. 2016; 33: 657-661
        • Indermaur MD
        • Shoup B
        • Tebes S
        • et al.
        The accuracy of frozen pathology at time of hysterectomy in patients with complex atypical hyperplasia on preoperative biopsy.
        Am J Obstet Gynecol. 2007; 196: e40-e42
        • Morotti M
        • Menada MV
        • Moioli M
        • et al.
        Frozen section pathology at time of hysterectomy accurately predicts endometrial cancer in patients with preoperative diagnosis of atypical endometrial hyperplasia.
        Gynecol Oncol. 2012; 125: 536-540
        • Stephan JM
        • Hansen J
        • Samuelson M
        • et al.
        Intra-operative frozen section results reliably predict final pathology in endometrial cancer.
        Gynecol Oncol. 2014; 133: 499-505
        • Montalto SA
        • Coutts M
        • Devaja O
        • et al.
        Accuracy of frozen section diagnosis at surgery in pre- malignant and malignant lesions of the endometrium.
        Eur J Gynaecol Oncol. 2008; 29: 435-440
        • Oz M
        • Ozgu E
        • Korkmaz E
        • et al.
        Utility of frozen section pathology with endometrial pre-malignant lesions.
        Asian Pac J Cancer Prev. 2014; 15: 6053-6057
        • Salman MC
        • Usubutun A
        • Dogan NU
        • et al.
        The accuracy of frozen section analysis at hysterectomy in patients with atypical endometrial hyperplasia.
        Clin Exp Obstet Gynecol. 2009; 36: 31-34
        • Oda K
        • Koga K
        • Hirata T
        • et al.
        Risk of endometrial cancer in patients with a preoperative diagnosis of atypical endometrial hyperplasia treated with total laparoscopic hysterectomy.
        Gynecol Minim Invasive Ther. 2016; 5: 69-73
        • Marcickiewicz J
        • Sunfeldt K.
        Accuracy of intraoperative gross visual assessment of myometrial invasion in endometrial cancer.
        Acta Obstet Gynecol Scand. 2011; 90: 846-851
        • Traen K
        • Holund B
        • Mogensen O
        Accuracy of preoperative tumor grade and intraoperative gross examination of myometrial invasion in patients with endometrial cancer.
        Acta Obstet Gynecol Scand. 2007; 86: 739-741
        • Frost JA
        • Webster KE
        • Bryant A
        • et al.
        Lymphadenectomy for the management of endometrial cancer.
        Cochrane Database Syst Rev. 2015; 9CD007585
        • Avci ME
        • Sadik S
        • Uçar MG
        A prospective study of rollerball endometrial ablation in the management of refractory recurrent symptomatic endometrial hyperplasia without atypia.
        Gynecol Obstet Investig. 2012; 74: 282-287
        • Kelly P
        • Dobbs SP
        • McCluggage WG
        Endometrial hyperplasia involving endometrial polyps: Report of a series and discussion of the significance in an endometrial biopsy specimen.
        BJOG. 2007; 114: 944-950
        • De Rijk SR
        • Steenbergen ME
        • Nieboer TE
        • et al.
        Atypical endometrial polyps and concurrent endometrial cancer: a systematic review.
        Obstet Gynecol. 2016; 128: 519-525

      Linked Article